Skip to main content
. 2021 Nov 2;11:21443. doi: 10.1038/s41598-021-01073-0

Figure 3.

Figure 3

A 75-year-old female (case 10, second episode) with Sjogren syndrome who used latanoprost 0.005% (Xalatan, Pfizer, New York, NY, US, with 0.02% BAK) for one month and dorzolamide 2%/timolol 0.5% combination (Cosopt; Merck & Co., Inc., Whitehouse Station, NJ, US, with 0.0075% BAK) for three days. She presented with type II pseudodendritic lesion from by grouped superficial punctate keratatitis in the left eye with the presumed diagnosis of HSK by the referral ophthalmologist (a, b). Dorzolamide 2%/timolol 0.5% combination was discontinued, followed by adding preservative free bimatoprost 0.03% (Lumigan, Allergan, Madison, NJ, US) and lubricants. The pseudodendritic lesion resolved within two weeks (c, d).